MARKET

BCLI

BCLI

Brainstorm Cell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

6.87
+0.82
+13.55%
After Hours: 6.87 0 0.00% 17:58 02/21 EST
OPEN
6.09
PREV CLOSE
6.05
HIGH
6.98
LOW
6.05
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
6.98
52 WEEK LOW
3.430
MARKET CAP
180.21M
P/E (TTM)
-7.0174
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of BCLI and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BCLI stock price target is 11.50 with a high estimate of 14.00 and a low estimate of 9.00.

EPS

BCLI News

More
  • BCLI: Phase 3 ALS Results in 4Q20
  • Zacks Small Cap Research · 3d ago
  • BrainStorm Cell down 3% premarket on FY 2019 results
  • seekingalpha · 4d ago
  • BrainStorm Cell Therapeutics Inc.'s (BCLI) CEO Chaim Lebovits on Q4 2019 Results - Earnings Call Transcript
  • Seeking Alpha - Transcript · 5d ago
  • BrainStorm Cell Therapeutics EPS misses by $0.15
  • seekingalpha · 5d ago

Industry

Biotechnology & Medical Research
+0.37%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About BCLI

Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's disease (PD), among others. Its subsidiary, Brainstorm Cell Therapeutics Ltd. (the Israeli Subsidiary), holds rights to commercialize the technology, NurOwn. NurOwn is in clinical development for the treatment of ALS. The Company has completed over two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center (Hadassah). The first study, a Phase I/II safety and efficacy study of NurOwn in ALS patients administered either intramuscularly or intrathecally. The Company conducted Phase IIa combined (intramuscular and intrathecal) treatment, dose-escalating trial. It had completed treatment of over 10 patients in its ALS Phase IIa NurOwn dose-escalating clinical trial.
More

Webull offers kinds of Brainstorm Cell Therapeutics Inc stock information, including NASDAQ:BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions.